Biochemical Engineering
Merck's Hilleman $58M invests in new Singapore vaccine hub
6th December 2021
Merck and Wellcome Trust’s Hilleman Laboratories on Monday unveiled a pilot manufacturing facility for vaccine development in Singapore. Comprising an R&D center and a clinical-stage factory, the new production and development hub will support Hilleman’s mission to create affordable biologics and vaccines for Singapore as well as low- and middle-income countries. Source: Fierce Pharma 6/12/2021
Back to group news